![Christy Oliger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christy Oliger
Directeur/Membre du Conseil chez
KARYOPHARM THERAPEUTICS INC.
Fortune : 924 640 $ au 31/05/2026
Profil
Christy J.
Oliger is currently an Independent Director at Nuvalent, Inc. since 2025, Karyopharm Therapeutics, Inc. since 2020, Replimune Group, Inc. since 2021, and Vera Therapeutics, Inc. since 2024.
Former roles include Independent Director at Sierra Oncology, Inc. from 2021 to 2022, Independent Director at Reata Pharmaceuticals, Inc. from 2021 to 2023, Director at Rayzebio, Inc. from 2023 to 2024, Independent Non-Executive Director at LAVA Therapeutics NV from 2023 to 2025, and Senior Vice President-Oncology Business Unit at Genentech, Inc. from 2017 to 2020.
Education includes undergraduate studies at the University of California, Santa Barbara.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUVALENT, INC. CLASS A 0,01 % | 16/06/2026 | 7 415 ( 0,01 % ) | 818 542 $ | 31/05/2026 |
| 21/05/2026 | 2 987 ( 0 % ) | 106 098 $ | 31/05/2026 | |
| 01/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 | |
| 21/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Christy Oliger
| Sociétés | Poste | Début |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Directeur/Membre du Conseil | 28/08/2020 |
| REPLIMUNE GROUP, INC. | Directeur/Membre du Conseil | 01/12/2021 |
| VERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/06/2024 |
| NUVALENT, INC. | Directeur/Membre du Conseil | 18/06/2025 |
Anciens postes connus de Christy Oliger
| Sociétés | Poste | Fin |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Directeur/Membre du Conseil | 07/11/2025 |
| RAYZEBIO, INC. | Directeur/Membre du Conseil | 26/02/2024 |
| REATA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/06/2023 |
| SIERRA ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/07/2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/07/2020 |
Formation de Christy Oliger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
94
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
LAVA Therapeutics NV
 LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
